ZA948180B - Pharmaceutical emulsion - Google Patents

Pharmaceutical emulsion

Info

Publication number
ZA948180B
ZA948180B ZA948180A ZA948180A ZA948180B ZA 948180 B ZA948180 B ZA 948180B ZA 948180 A ZA948180 A ZA 948180A ZA 948180 A ZA948180 A ZA 948180A ZA 948180 B ZA948180 B ZA 948180B
Authority
ZA
South Africa
Prior art keywords
pct
pharmaceutical emulsion
date
sec
pub
Prior art date
Application number
ZA948180A
Other languages
English (en)
Inventor
Kjell Hjalmar Andersson
Anna-Carin Hansson
Ralf Christer Westerlund
Eva Christina Byroed
Margaretha Nordlander
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of ZA948180B publication Critical patent/ZA948180B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ZA948180A 1993-11-12 1994-10-18 Pharmaceutical emulsion ZA948180B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9303744A SE9303744D0 (sv) 1993-11-12 1993-11-12 Pharmaceutical emulsion

Publications (1)

Publication Number Publication Date
ZA948180B true ZA948180B (en) 1995-05-12

Family

ID=20391731

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA948180A ZA948180B (en) 1993-11-12 1994-10-18 Pharmaceutical emulsion

Country Status (31)

Country Link
US (1) US5739152A (xx)
EP (1) EP0727997B1 (xx)
JP (1) JP3759951B2 (xx)
KR (1) KR100345627B1 (xx)
CN (1) CN1072934C (xx)
AT (1) ATE213158T1 (xx)
AU (1) AU678650B2 (xx)
CA (1) CA2176360C (xx)
CZ (1) CZ290772B6 (xx)
DE (1) DE69429871T2 (xx)
DK (1) DK0727997T3 (xx)
EE (1) EE03223B1 (xx)
EG (1) EG20764A (xx)
ES (1) ES2172572T3 (xx)
FI (1) FI116999B (xx)
HK (1) HK1013261A1 (xx)
HU (1) HU223142B1 (xx)
IL (1) IL111345A (xx)
IS (1) IS2036B (xx)
MY (1) MY121201A (xx)
NO (1) NO314877B1 (xx)
NZ (1) NZ276197A (xx)
PL (1) PL181462B1 (xx)
PT (1) PT727997E (xx)
RU (1) RU2144358C1 (xx)
SA (1) SA94150314B1 (xx)
SE (1) SE9303744D0 (xx)
SK (1) SK283271B6 (xx)
UA (1) UA40633C2 (xx)
WO (1) WO1995013066A1 (xx)
ZA (1) ZA948180B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
AU764001B2 (en) * 1998-05-29 2003-08-07 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
SE9804002D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New manufacturing process
DE10036871A1 (de) 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US7387790B2 (en) 2001-06-15 2008-06-17 Cornerstone Pharmaceuticals Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
PT1615646E (pt) * 2003-04-08 2015-02-12 Progenics Pharm Inc Formulações farmacêuticas com metilnaltrexona
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
EP2137191B8 (en) 2007-03-29 2016-06-08 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
DK2565195T3 (en) * 2007-03-29 2015-06-29 Wyeth Llc PERIPHERAL OPIOID RECEPTOR AND ANTAGONISTS AND USES THEREOF
JP5358587B2 (ja) * 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッド （ｒ），（ｒ）−２，２’−ビス−メチルナルトレキソンの製造及び用途
EA201170287A1 (ru) * 2008-08-01 2011-10-31 Дзе Медсинз Компани Фармацевтические композиции и способы их стабилизации
EP2719386A1 (en) * 2008-08-01 2014-04-16 The Medicines Company Pharmaceutical compositions and methods for producing low impurity concentrations of the same
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) * 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
WO2010107081A1 (ja) * 2009-03-19 2010-09-23 第一三共株式会社 包装により安定保存された固形製剤
CN101780036B (zh) * 2010-03-30 2011-11-16 武汉武药科技有限公司 丁酸氯维地平脂微球注射液及其制备方法
BR112013008601B1 (pt) 2010-10-12 2020-03-31 Chiesi Farmaceutici S.P.A. Formulações de emulsão de clevidipina contendo agentes antimicrobianos
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
CN102531998A (zh) * 2010-12-09 2012-07-04 天津药物研究院 α型多晶型丁酸氯维地平结晶、其制备方法、用途和药物组合物
CN102525918A (zh) * 2010-12-30 2012-07-04 天津药物研究院 一种丁酸氯维地平的脂肪乳注射液及其制备工艺
US20120213855A1 (en) * 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
EP2694063A1 (en) * 2011-04-01 2014-02-12 The Medicines Company Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage
JP6339940B2 (ja) 2011-12-20 2018-06-06 ビョーメ バイオサイエンシズ ピーブイティー．リミテッド 真菌感染症の治療用の局所用オイル組成物
ES2671639T3 (es) 2012-10-26 2018-06-07 Chiesi Farmaceutici S.P.A. Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca
CN103110580B (zh) * 2013-02-20 2014-09-17 北京德立福瑞医药科技有限公司 丁酸氯维地平注射剂
US20160058775A1 (en) * 2013-04-12 2016-03-03 Vyome Biosciences Pvt. Ltd. Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections
US11737989B2 (en) 2014-05-19 2023-08-29 Chiesi Farmaceutici S.P.A. Clevidipine nanoparticles and pharmaceutical compositions thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315805A1 (de) * 1983-04-30 1984-11-08 Bayer Ag, 5090 Leverkusen Wirkstoffzubereitungen
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
DE3515335C2 (de) * 1985-04-27 1995-01-26 Bayer Ag Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung
DE4217842A1 (de) * 1992-05-29 1993-12-02 Dietl Hans Calciumantagonisten enthaltende pharmazeutische Zubereitung zur intravenösen und intrakoronaren Applikation sowie Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
HK1013261A1 (en) 1999-08-20
IS4224A (is) 1995-05-13
KR100345627B1 (ko) 2003-03-15
JPH09505045A (ja) 1997-05-20
DE69429871T2 (de) 2002-08-22
JP3759951B2 (ja) 2006-03-29
EE03223B1 (et) 1999-10-15
CA2176360C (en) 2005-08-23
CA2176360A1 (en) 1995-05-18
UA40633C2 (uk) 2001-08-15
NO961898L (no) 1996-06-25
CZ133896A3 (en) 1996-09-11
MY121201A (en) 2006-01-28
SA94150314B1 (ar) 2005-06-14
FI961999A (fi) 1996-05-10
ES2172572T3 (es) 2002-10-01
HUT74474A (en) 1996-12-30
AU1037195A (en) 1995-05-29
HU9601268D0 (en) 1996-07-29
ATE213158T1 (de) 2002-02-15
EG20764A (en) 2000-01-31
IS2036B (is) 2005-08-15
DK0727997T3 (da) 2002-04-22
DE69429871D1 (de) 2002-03-21
CN1072934C (zh) 2001-10-17
NO314877B1 (no) 2003-06-10
US5739152A (en) 1998-04-14
HU223142B1 (hu) 2004-03-29
PL314263A1 (en) 1996-09-02
NZ276197A (en) 1997-04-24
PL181462B1 (pl) 2001-07-31
RU2144358C1 (ru) 2000-01-20
CN1136774A (zh) 1996-11-27
EP0727997A1 (en) 1996-08-28
PT727997E (pt) 2002-07-31
AU678650B2 (en) 1997-06-05
SK283271B6 (sk) 2003-04-01
FI961999A0 (fi) 1996-05-10
SE9303744D0 (sv) 1993-11-12
SK59796A3 (en) 1996-12-04
IL111345A0 (en) 1994-12-29
WO1995013066A1 (en) 1995-05-18
IL111345A (en) 2000-08-31
CZ290772B6 (cs) 2002-10-16
FI116999B (fi) 2006-05-15
NO961898D0 (no) 1996-05-10
EP0727997B1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
EG20764A (en) Pharmaceutical emulsion
PL318901A1 (en) Consolvent-type thyrilasade preparation for parenteral administration
DE69425431D1 (en) 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
NO962162L (no) Dipeptider som bevirker frigjöring av veksthormon
IL117112A0 (en) Solid active compound preparations
EG20540A (en) New emulsion formulation
PT692028E (pt) Farmacos baseados em papilomavirus
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
SG102892G (en) Composition of pregnanolole comprising a stable oil-in-water emulsion
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
SE9303853L (sv) Användning av en inositoltrisfosfatester för beredning av läkemedel
DK0850225T3 (da) Mellemprodukt til fremstilling af en farmaceutisk aktiv forbindelse